TaiAn Technologies Corporation

AnBogen Therapeutics is a clinical-stage biotechnology company focused on the development of precision anti-cancer drugs aimed at addressing unmet medical needs in oncology. The company is committed to improving the lives of cancer patients worldwide by creating innovative therapeutics that target specific cancer types. AnBogen's research emphasizes the development of multiple oncology inhibitors, particularly for the treatment of lung cancer, thereby establishing a differentiated pipeline in precision oncology. By bridging the gap between research and clinical development, AnBogen seeks to deliver effective solutions for cancer treatment, ultimately striving for the potential cure of various cancers.

Developer of innovative protein degradation drugs designed to treat cancer, neurodegenerative and aging-related diseases. The company develops a drug pipeline, using an AI-enabled platform to discover drug candidates, which target and degrade disease-related proteins, enabling researchers, clinicians, and pharmaceutical companies to access a novel class of drugs that address life-threatening and life-impairing diseases plagued by drug resistance.

Aprinoia Therapeutics Inc. is a clinical-stage biotechnology company focused on advancing brain health through innovative diagnostic tools and therapies for neurodegenerative diseases. Founded in 2015 and headquartered in Taipei, Taiwan, with additional locations in China and Japan, Aprinoia develops imaging-based diagnostics, including 18F-PM-PBB3, a tau positron-emission tomography (PET) tracer that aids in the diagnosis of tauopathies. The company also manufactures an alpha-synuclein PET imaging tracer. By targeting protein aggregates associated with conditions like Alzheimer's and Parkinson's diseases, Aprinoia aims to enhance precision medicine in neuroscience and improve patient outcomes. The company's commitment to addressing the complexities of neurodegenerative diseases positions it as a leader in the development of first-in-class and best-in-class diagnostic and therapeutic solutions.

Sapience Therapeutics, Inc. is a biotechnology company focused on discovering and developing peptide-based therapeutics aimed at addressing high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company is advancing novel therapies to meet significant unmet medical needs. Its lead product, ST101, is an inhibitor of the transcription factor C/EBPß, which is overexpressed in various cancers and plays a critical role in cellular differentiation, tumor survival, and proliferation. ST101 reduces the expression of several target genes and proteins associated with cancer cell survival and growth, inducing selective cytotoxicity in tumor types such as breast cancer, melanoma, prostate cancer, glioblastoma multiforme, lung cancer, and acute myeloid leukemia. The company aims to develop first-in-class treatments for deadly conditions, with a particular focus on glioblastoma, the most aggressive form of brain cancer.